Kisspeptin
KP-54, KP-10, KP-13, Metastin, KISS1 peptide
The Ground Truth Score
four plain questions, never one numberOne of the few peptides with actual RCT data, but almost all of it is for fertility and sexual dysfunction in clinic settings, not wellness.
Bottom line
Kisspeptin is a genuine neuroendocrine signaling peptide (encoded by the KISS1 gene) that sits upstream of the entire reproductive hormone cascade, with controlled human trials showing real effects on LH/FSH and sexual brain processing, but the evidence is narrow, short-term, and almost entirely outside the wellness/optimization context it gets hyped for.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
Can you legally get it?
Research-onlyNo legal consumer routeSold labeled 'for research use only, not for human consumption.' There is no approved product, no compounding path, and no one verifying identity, purity, or dose. That label is not a formality, it is the entire legal basis on which it can be sold to you at all.
No FDA-approved product and no 503A compounding route. Sold labeled for research use only, which is the legal basis on which it can be sold at all.
Legal status as of 2026-07-25. This is a separate axis from the grades above, and it does not move them. A vote about who may legally prepare a compound is not evidence that the compound works.
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓100-200 mcg SubQ once daily (community reported); no approved or established wellness protocol
Reported, not prescribed. Verify your vial and your math.
The gist
- One of the rare peptides with actual RCT data, but the trials are for IVF triggers and sexual dysfunction in clinical settings, not general optimization.
- The mechanism is real and well-characterized: upstream of the entire HPG axis, kisspeptin pulls the lever that starts testosterone and LH production.
- The catch is a big one: run it daily and KISS1R desensitizes, which can paradoxically tank LH instead of raising it, and compounded kisspeptin-10 lost its legal US pathway in October 2024.
First documented human use
2003, when two independent research groups (de Roux et al. and Seminara et al.) identified loss-of-function KISS1R mutations causing hypogonadotropic hypogonadism in humans; first exogenous administration in humans was published around 2005 by Dhillo et al. at Imperial College London.
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. We grade each one below.
- Raises LH and testosterone naturally by stimulating the root of the HPG axis
- Improves libido and sexual desire in men and women
- Safe alternative trigger for oocyte maturation in IVF (reduced OHSS risk)
- Supports hypothalamic function and pulsatile GnRH signaling
- May improve male factor infertility and spermatogenesis
The data behind each bullet
What actually backs it
Kisspeptin administration raises LH and testosterone in healthy men
Multiple small controlled trials in healthy male volunteers confirm acute LH/FSH and downstream testosterone elevation after IV or SC kisspeptin-54 and kisspeptin-10. Effects are transient (minutes to hours) and receptor desensitization occurs with sustained exposure. Not studied as a chronic testosterone-optimization strategy.
PMC4063702 - The kisspeptin-GnRH pathway in human reproductive health and disease (2014 review) ↗Kisspeptin improves sexual desire and arousal in men with HSDD
2023 JAMA Network Open RCT (n=32 men with HSDD, double-blind crossover) showed kisspeptin significantly modulated brain activity in sexual processing regions vs. placebo, increased penile tumescence by up to 56%, and improved self-reported sexual happiness. Only one published RCT, small n, no long-term follow-up. All HSDD RCT data originates from a single institution (Imperial College London); no independent replication across centers exists.
PMC9898824 - Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With HSDD (JAMA Network Open 2023) ↗Kisspeptin-54 is an effective and safer trigger for oocyte maturation in IVF
Phase 2 RCT (n=60 high-OHSS-risk women) showed 95% oocyte maturation rate, clinical pregnancy rates up to 77%, and zero cases of moderate, severe, or critical OHSS at optimized dose (9.6 nmol/kg). Multiple published trials across centers. This is the strongest evidence base and is the closest to clinical adoption. Note: kisspeptin-54 is still investigational as an IVF trigger; it is not approved for this use by any regulatory agency as of the authoring of this profile.
PMC4570165 - Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of OHSS During IVF (Phase 2 RCT, 2015) ↗Kisspeptin reverses hormonal suppression in hypothalamic amenorrhoea
Controlled studies show exogenous kisspeptin restores LH pulsatility and gonadotropin secretion in women with hypothalamic amenorrhoea, including via intranasal delivery. Promising but still investigational, not an approved treatment.
PMC12018048 - Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans (eBioMedicine / The Lancet, 2025) ↗Kisspeptin improves sexual desire and brain processing in women with HSDD
A parallel RCT in 32 women with HSDD (same Imperial College London group, 2022) showed kisspeptin enhanced brain responses to positive emotional stimuli and improved sexual desire ratings vs. placebo. Similar limitations to the male trial: single RCT, short-term, administered in clinical setting. All HSDD RCT data originates from a single institution (Imperial College London); no independent replication across centers exists.
PMC9606846 - Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial (JAMA Network Open 2022) ↗Prove it
Can you tell if it's working?
The honest test: if it's working, is there any objective way to see it — a blood marker, a scan, a wearable? For a lot of peptides the answer is no, and that's worth knowing before you spend on labs or gear.
The only clean objective signal is the HPG axis itself — acute LH in blood, plus (women restoring cycles only) at-home PdG confirmation that ovulation actually occurred; the libido/mood effects have no consumer objective tracker.
Bloodwork
A lab moves, but it's noisy, indirect, or off-target — treat it as a hint, not proof.
Kisspeptin activates KISS1R on hypothalamic GnRH neurons, driving pulsatile GnRH -> pituitary LH/FSH -> gonadal testosterone/estradiol. Every step is a routine LabCorp/Quest analyte, so acute receptor engagement is visible in standard bloodwork. The catch: this only reads cleanly as an acute in-clinic challenge (timed pre/post single dose), and chronic daily self-dosing desensitizes KISS1R, so routine bloodwork does not track the efficacy of how people actually use it.
Clear rise above a same-session pre-dose baseline on a timed post-dose draw. In controlled kisspeptin-54 infusion mean LH nearly tripled vs saline (Dhillo 2005). This is the single cleanest proof of action, but only as an acute challenge, not a routine random draw.
Most proximal measurable human effect: GnRH-driven pituitary LH release, detectable within ~10-45 min of a dose. RCT-validated in humans.
Lagging, modest rise a few hours after dosing (peaked ~180 min in Dhillo 2005, ~15% over baseline); more variable than LH. Draw fasting AM to control diurnal variation.
Downstream Leydig-cell steroidogenesis driven by the LH pulse; a slower, indirect confirmation the signal reached the gonad.
Small rise above pre-dose baseline on the same timed draw; in Dhillo 2005 only ~22% (3.2 -> 3.9 U/L), the weakest and noisiest of the signals. Do not rely on it alone.
Co-secreted with LH under GnRH drive, but the human FSH response to kisspeptin is blunt and often within assay noise.
Rise reflecting kisspeptin-driven gonadotropin/ovarian response, strongly cycle-phase dependent; interpret only against a same-phase baseline. The softest, hardest-to-read proxy here.
The female LH/estradiol response to kisspeptin is sexually dimorphic and cycle-stage dependent, so it is a real but much noisier proxy than LH in men.
Draw baseline
Same-session pre-injection draw (immediately before the dose); fasting AM for testosterone. Because kisspeptin acts acutely, the baseline must be a pre-dose sample, not a weeks-earlier one.
Retest
Timed post-dose, same session: LH at ~30-45 min, testosterone at ~2-4 hr. This is an acute challenge test, NOT a weeks-later retest. Chronic daily dosing desensitizes KISS1R, so a flat LH measured weeks in cannot distinguish "not working" from receptor downregulation.
Read this before you spend on labs
Graded partial, not direct: the acute pre/post LH rise on a single timed dose is RCT-established biology, but it is a clinic-based challenge that wellness users doing 100-200 mcg daily essentially never capture, and routine random bloodwork does not track their actual use pattern. Traps: (1) continuous daily dosing desensitizes KISS1R and can flatten or even suppress LH, so a null weeks-later result is uninformative; (2) in HPG-suppressed men (TRT/AAS) the LH response is blunted, so a null there says nothing about the drug. Downstream testosterone rises are genuine but lag and are modest (~15%); FSH is often within assay noise (~22%); the female estradiol signal is cycle-dependent and soft. Reserve LH as the meaningful readout and only under a timed acute-challenge protocol.
Other ways to track it
At-home urinary hormone testing — urinary LH (OPK/Mira/Inito) to time a suspected surge, with PdG (pregnanediol glucuronide, e.g. Proov) as the load-bearing confirmation that ovulation truly occurred
Only meaningful in a woman using kisspeptin to restore ovulation (hypothalamic amenorrhea / IVF-trigger context). A working response is the return of a genuinely ovulatory cycle in someone previously anovulatory — confirmed by a post-ovulatory PdG rise, not by urinary LH alone (kisspeptin directly stimulates LH, so a urinary LH bump can reflect the drug's pharmacodynamic effect rather than a true spontaneous surge; PdG is what proves a corpus luteum formed). Does NOT apply to men or to the libido/HSDD use case, where there is no objective urine readout. Home OPK reliability is shaky around an exogenously stimulated axis, and real clinical ovulation induction is monitored by ultrasound/serum, not home kits.
Kisspeptin acts upstream of GnRH -> LH/FSH -> gonadal steroids, and its flagship human efficacy endpoint is restored/triggered ovulation. PdG is a validated at-home marker that ovulation genuinely occurred, making it a non-invasive downstream proxy of the same axis the blood LH challenge measures — not an independent readout, and narrow to the ovulation-restoration population only.
Bottom line
Kisspeptin has essentially ONE objective efficacy signal: the reproductive (HPG) axis it drives. Blood already owns that as an acute timed LH challenge, but it is only interpretable acutely — daily dosing desensitizes KISS1R, so routine weeks-later bloodwork misleads. The single non-blood objective readout is at-home urinary ovulation confirmation, and only for women using it to restore ovulation; the load-bearing marker there is PdG (proof ovulation occurred), since urinary LH alone can just reflect the drug stimulating LH. It is a downstream proxy of the same axis, not an independent one, and near-empty for the typical user. No stool, CGM, VO2max, DEXA, sleep/wearable, or body-composition endpoint applies. Kisspeptin's marquee non-reproductive effects (sexual desire, emotional/brain processing, penile tumescence) were measured only by research-only fMRI and in-lab plethysmography from a single largely unreplicated center; there is no consumer-accessible objective tracker for them. So for the typical male optimization/libido user there is no non-blood objective way to verify it is working — the honest tracker is subjective response plus, if desired, an acute LH blood challenge.
Logging baseline vs retest is the whole game. The Truth Tracker is our free log for bloodwork, DEXA, genetics, and wearable data — bring your own numbers.
How to track it →Mechanism
How it's assumed to work
Assumed · theoretical pathway
Kisspeptin binds to its receptor KISS1R (also called GPR54) on GnRH neurons in the hypothalamus. This is the single most upstream regulatory gate of the hypothalamic-pituitary-gonadal axis. Receptor activation triggers GnRH pulse release, which drives pituitary LH and FSH secretion, which in turn stimulates gonadal sex hormone production (testosterone in men, estrogen/progesterone in women) and gametogenesis. Kisspeptin neurons also integrate environmental and metabolic signals (energy state, circadian rhythm, photoperiod, stress) to gate reproduction. The sexual desire and brain processing effects observed in HSDD trials are assumed to reflect both peripheral hormonal changes and direct central kisspeptin signaling, but the relative contributions are not established in humans.
Dosing & handling
What users and clinicians report
Wellness community most commonly reports kisspeptin-10 at 100-200 mcg subcutaneous once daily, often 30-60 minutes before bed or before anticipated sexual activity, on a 30-days-on/30-days-off cycle. Some protocols cite 6-10 mcg/kg body weight. Clinical research used kisspeptin-54 at much higher doses (3.2-12.8 nmol/kg IV or SC) in supervised settings. Intranasal kisspeptin-54 has been studied at 6.4 nmol/kg.
None of these doses are prescribed or approved for any wellness or optimization purpose. The biggest dosing risk is continuous daily administration causing KISS1R desensitization and paradoxically suppressing the HPG axis rather than stimulating it. Clinical doses were administered as single injections in monitored trials, not daily wellness stacks. Compounded kisspeptin-10 now lacks a legal US compounding pathway following the October 2024 PCAC vote.
Timing & food
In clinical trials, kisspeptin was administered as single acute injections to elicit a timed hormonal surge (e.g., 36-38 hours before oocyte retrieval in IVF). Wellness protocols citing pre-bed or pre-sexual-activity timing are extrapolating from the transient LH/libido response seen in research. The very short half-life means timing relative to desired effect matters more than with longer-acting peptides.
Half-life
KP-10 has a half-life of approximately 3.8-4.1 minutes in humans. KP-54 has a half-life of approximately 27.6 minutes. Both are rapidly degraded by circulating proteases, particularly at the N-terminus. Neither persists beyond roughly 30 minutes post-injection in blood.
Reconstitution sensitivity
Moderate sensitivity. Lyophilized powder should be reconstituted with bacteriostatic water (BAC water), not sterile saline (shorter shelf life). Avoid vigorous shaking. Store reconstituted peptide refrigerated (2-8C) and use within 28-30 days. KP-10 is particularly susceptible to N-terminal proteolysis and oxidation of the tryptophan residue; minimize freeze-thaw cycles.
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
Low-moderate. Kisspeptin has a small but growing wellness community presence, primarily in men pursuing natural testosterone optimization or libido enhancement. Volume is much lower than GH secretagogues or BPC-157.
Consistency
Mixed. Users on TRT cannot attribute any benefit to kisspeptin specifically. Off-TRT reports describe modest libido improvement in some users and no effect in others. IVF and HSDD use cases map to real clinical data but are not wellness optimization contexts.
Source credibility
Low-moderate. Most self-reports come from people already on complex stacks. The clinical trial signal (IVF, HSDD) is real and peer-reviewed but does not map cleanly to the 'raise T, improve libido' wellness framing. Anecdote quality is poor relative to the actual research quality on this peptide.
- Anecdote: Some male users off TRT report noticeably increased morning erections and libido within 1-2 weeks at 100-200 mcg/day, though attributability is low without pre/post labs.
- Anecdote: Users on TRT typically report no perceptible effect, consistent with the fact that the HPG axis is already suppressed and LH is not the rate-limiting step.
- Anecdote: A subset of users report flushing, headache, or mild nausea within 30 minutes of injection, consistent with the mild adverse events seen in clinical studies.
- Anecdote: Several forum reports describe initial benefit followed by loss of effect after 3-4 weeks of daily use, which is mechanistically plausible given KISS1R desensitization data from research settings.
Placebo risk, Moderate
Primary wellness claims (libido, energy, 'hormonal optimization') are highly subjective. The legitimate clinical effects (LH/FSH elevation, brain sexual processing changes) require measurement to confirm, and most self-experimenters have no baseline labs. Libido is especially susceptible to expectation effects. Objective markers like serum LH could distinguish real from placebo response but are rarely tracked in wellness use.
Risk panel
What could go wrong
Adverse events
Across 150+ human subjects in published trials, adverse events have been mild and transient: injection site reactions (redness, swelling, tenderness), transient flushing, mild headache, nausea, and lightheadedness. No serious adverse events related to kisspeptin have been reported in any published clinical study. All trials were short-duration single-session or brief window administrations; this is not a long-term safety database.
Theoretical concerns
Receptor desensitization (KISS1R downregulates rapidly with sustained stimulation via beta-arrestin internalization) could paradoxically suppress LH/FSH/testosterone with continuous daily use. This risk is mechanistically established and entirely unstudied in humans with chronic wellness dosing. Supraphysiologic or ill-timed dosing could disrupt GnRH pulsatility. Potential interference with fertility in men (excessive kisspeptin tone may paradoxically impair sperm function). No data on effects in women who are or could become pregnant outside of IVF contexts.
Contraindications
Hormone-sensitive cancers (KISS1 has established cancer biology beyond reproduction; it was originally identified as a metastasis suppressor, and the cancer biology has no human safety characterization in wellness populations). Active pregnancy outside controlled medical setting. Hormone-dependent conditions. Anyone on GnRH agonists or antagonists (mechanistic conflict). KISS1R mutations (some individuals have variant receptor function).
Honest unknowns
No long-term safety data beyond short-term research dosing windows. No data on chronic daily use in healthy people. No data on interactions with TRT, GLP-1 agonists, or exogenous peptide stacks. No pharmacovigilance database for wellness use. Optimal isoform (KP-10 vs KP-54), dose, route, and cycling interval for any off-label purpose are entirely undefined.
Confound watch
Often used alongside TRT (which already supplies exogenous testosterone, making any 'kisspeptin-raised T' claim unattributable). Stacked with GH peptides like ipamorelin or sermorelin (confounds libido and body comp outcomes). Context of IVF trials includes exogenous gonadotropins. In HSDD trials, pre-existing psychological or relationship factors are not fully controlled. Online self-reports frequently combine kisspeptin with PT-141 (bremelanotide), making libido attribution impossible.
History
Discovery → first use → status
- 1996KISS1 gene identified as a metastasis suppressor in malignant melanoma research; named after Hershey, Pennsylvania (home of Hershey Kisses chocolate), where the discovery was made.
- 2003Two independent groups (de Roux in France, Seminara at Harvard) publish simultaneous findings that loss-of-function mutations in KISS1R cause hypogonadotropic hypogonadism, establishing kisspeptin as the gatekeeper of human puberty and reproduction.
- 2014Jayasena, Abbara, Dhillo and colleagues at Imperial College London publish the first proof-of-concept human IVF trial using kisspeptin-54 as an oocyte maturation trigger, resulting in live births and no serious OHSS. Published in the Journal of Clinical Investigation (PMID 25036713). A related Lancet abstract (Abbara et al., DOI 10.1016/S0140-6736(14)60280-4) was published in the same year. Marks the transition from basic science to clinical application.
- 2022-2023Back-to-back RCTs in JAMA Network Open (men 2023, women 2022) demonstrate kisspeptin modulates sexual brain processing in people with HSDD, generating mainstream press coverage and driving wellness-market interest. Both trials conducted at Imperial College London; independent replication is pending.
- 2024October 29, 2024: FDA Pharmacy Compounding Advisory Committee (PCAC) voted 11-0 to recommend EXCLUDING kisspeptin-10 from the 503A Bulks List, the list of substances that compounding pharmacies may legally use. The committee cited insufficient human safety data, mechanistic concerns about unintended endocrine effects, and a lack of reproducible efficacy data outside small or open-label trials. This vote effectively removes the legal compounding pathway for kisspeptin-10 in the United States. FDA meeting record: https://www.fda.gov/advisory-committees/advisory-committee-calendar/october-29-2024-meeting-pharmacy-compounding-advisory-committee-10292024
Verification
The COA standard, applied
Grade adversarially re-reviewed 2026-06-21 and downgraded to reflect the absence of formal human safety/efficacy data. Citations re-verified 2026-06-22: all PMIDs confirmed real and resolving. History corrected (first IVF live birth trial was JCI 2014, PMID 25036713, not The Lancet). October 2024 FDA PCAC 11-0 exclusion vote added to risk and history. HSDD single-institution dependence noted in claim basis. IVF investigational status flagged in claim text and dosing caveat.
The full verification standard →Sources
Where this comes from
- Kisspeptin and its Current Clinical Status - A Systematic Review (PubMed 2024, PMID 38265397) ↗· Systematic review of 33 clinical trial records; provides the most current synthesis of human evidence across indications.
- Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With HSDD (PMC 2023, PMC9898824) ↗· The RCT that generated most of the mainstream press. Double-blind crossover, n=32, published JAMA Network Open. Imperial College London; not independently replicated.
- Kisspeptin-54 IVF Trigger Efficacy - Phase 2 Trial (PMC 2015, PMC4570165) ↗· Strongest evidence in the kisspeptin literature. Phase 2 RCT with live birth outcomes, zero OHSS at optimized dose. Kisspeptin-54 remains investigational as an IVF trigger with no regulatory approval as of this profile.
- The kisspeptin-GnRH pathway in human reproductive health and disease (PMC 2014, PMC4063702) ↗· Foundational mechanism review covering the full HPG axis upstream control by kisspeptin; explains both the genuine biology and the limits of translation to wellness use.
- FDA PCAC October 29, 2024 Meeting - Kisspeptin-10 503A Bulks Review (FDA.gov) ↗· Official FDA record of the PCAC meeting at which kisspeptin-10 was voted 11-0 for exclusion from the 503A Bulks List. Cites insufficient safety data and unintended endocrine effect concerns.
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.